HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety
- 16 September 2021
- journal article
- editorial
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 52 (10-11) , 894-898
Abstract
Treatment options for the anemia of chronic kidney disease (CKD) continue to expand. Several hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are undergoing clinical testing and seeking regulatory approval. Erythropoiesis-stimulating agents (ESAs) have been the cornerstone of anemia therapy since 1989, when first-in-class recombinant human erythropoietin was approved. The rise in hemoglobin (Hb) with ESAs demanded greater need for iron and paradoxically greater iron losses due to the higher Hb concentration. This exacerbated iron deficiency led to markedly increased use of intravenous (IV) iron. ESAs, especially at larger dosages aimed to target higher target Hb levels, increase the risk of cardiovascular and thrombotic events, cancer, and death. Prescribed IV iron therapy, while apparently safer, has limited long-term safety evidence and fills iron stores well beyond the normal range, which in part overcomes hepcidin-mediated iron blockade.Keywords
This publication has 7 references indexed in Scilit:
- Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)Nephrology Dialysis Transplantation, 2021
- Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing DialysisNew England Journal of Medicine, 2021
- Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKDNew England Journal of Medicine, 2021
- Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney diseaseKidney International Supplements, 2021
- RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to DialysisKidney International Reports, 2021
- Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in JapanJournal of the American Society of Nephrology, 2020
- C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysisNephrology Dialysis Transplantation, 2011